NYSE : ELAN
Elanco Animal Health Incorporated — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 23.06 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 11.52B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 11.52B |
| Enterprise Value | 15.22B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 499.62M |
| Shares Outstanding | 499.62M |
| Shares Change (YoY) | -0.50% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 0.71% |
| Owned by Institutions (%) | 114.41% |
| Float | 495.40M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 19.51 |
| PS Ratio | 2.30 |
| Forward PS | 2.19 |
| PB Ratio | 1.75 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 30.40 |
| P/OCF Ratio | 18.67 |
| PEG Ratio | 1.77 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.03 |
| EV / EBITDA | 15.12 |
| EV / EBIT | 44.78 |
| EV / FCF | 40.17 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.05 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 3.92 |
| Debt / FCF | 11.17 |
| Interest Coverage | 1.25 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -2.98% |
| Return on Assets (ROA) | 1.56% |
| Return on Invested Capital (ROIC) | 3.29% |
| Return on Capital Employed (ROCE) | 2.90% |
| Weighted Average Cost of Capital (WACC) | 11.39% |
| Revenue Per Employee | $507,071 |
| Profits Per Employee | -$20,101 |
| Employee Count | 9,900 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 1.30 |
Taxes
| Measure | Value |
|---|
| Income Tax | 33.00M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.72 |
| 52-Week Price Change | +2.08% |
| 50-Day Moving Average | 23.12 |
| 200-Day Moving Average | 23.79 |
| Relative Strength Index (RSI) | 52.46 |
| Average Volume (20 Days) | 4,653,386 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 31.11M |
| Short Previous Month | 31.81M |
| Short % of Shares Out | 6.23% |
| Short % of Float | 6.28% |
| Short Ratio (days to cover) | 5.57 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 5.02B |
| Gross Profit | 2.78B |
| Operating Income | 340.00M |
| Pretax Income | -166.00M |
| Net Income | -199.00M |
| EBITDA | 1.01B |
| EBIT | 340.00M |
| Loss Per Share | -$0.41 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 530.00M |
| Total Debt | 4.23B |
| Net Cash | -3.70B |
| Net Cash Per Share | -$7.41 |
| Equity (Book Value) | 6.59B |
| Book Value Per Share | 13.19 |
| Working Capital | 1.95B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 617.00M |
| Capital Expenditures | -238.00M |
| Depreciation & Amortization | 667.00M |
| Net Borrowing | 12.00M |
| Free Cash Flow | 379.00M |
| FCF Per Share | $0.76 |
Margins
| Measure | Value |
|---|
| Gross Margin | 55.36% |
| Operating Margin | 6.77% |
| Pretax Margin | -3.31% |
| Profit Margin | -3.96% |
| EBITDA Margin | 20.06% |
| EBIT Margin | 6.77% |
| FCF Margin | 7.55% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.50% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.76% |
| FCF Yield | 3.29% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $30.23 |
| Price Target Difference | 31.09% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | 6.34% |
| EPS Growth Forecast (3Y) | 15.26% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.33 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |